Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-12 4:05 pm Purchase |
2024-12-31 | 13G | Verrica Pharmaceuticals Inc. VRCA |
Caligan Partners LP | 15,856,653 9.990% |
15,856,653 (New Position) |
Filing History |
| 2024-09-18 4:30 pm Sale |
2024-09-16 | 13D | Alimera Sciences, Inc. ALIM |
Caligan Partners LP | 0 0.000% |
-17,635,154 (Position Closed) |
Filing History |
| 2024-09-12 4:22 pm Purchase |
2024-09-10 | 13D | Liquidia Corporation LQDA |
Caligan Partners LP | 8,118,592 9.800% |
1,123,595 (+16.06%) |
Filing History |
| 2024-09-04 5:51 pm Sale |
2024-08-30 | 13D | Liquidia Corporation LQDA |
Caligan Partners LP | 6,994,997 9.300% |
-3,365,948 (-32.49%) |
Filing History |
| 2024-06-24 7:30 pm Unchanged |
2024-06-21 | 13D | Alimera Sciences, Inc. ALIM |
Caligan Partners LP | 17,635,154 33.200% |
0 (Unchanged) |
Filing History |
| 2024-05-30 4:31 pm Purchase |
2024-05-28 | 13D | Anika Therapeutics, Inc. ANIK |
Caligan Partners LP | 1,435,993 9.700% |
12,500 (+0.88%) |
Filing History |
| 2024-03-06 7:30 pm Purchase |
2024-03-04 | 13D | Anika Therapeutics, Inc. ANIK |
Caligan Partners LP | 1,423,493 9.700% |
342,133 (+31.64%) |
Filing History |
| 2024-01-08 5:00 pm Sale |
2024-01-05 | 13D | Standard BioTools Inc. LAB |
Caligan Partners LP | 7,042,413 2.400% |
-755,041 (-9.68%) |
Filing History |
| 2023-12-14 4:40 pm Purchase |
2023-12-14 | 13D | Liquidia Corporation LQDA |
Caligan Partners LP | 10,360,945 15.300% |
3,193,282 (+44.55%) |
Filing History |
| 2023-09-11 06:01 am Purchase |
2023-09-08 | 13D | Anika Therapeutics, Inc. ANIK |
Caligan Partners LP | 1,081,360 7.400% |
179,274 (+19.87%) |
Filing History |
| 2023-08-17 08:00 am Purchase |
2023-08-09 | 13D | Anika Therapeutics, Inc. ANIK |
Caligan Partners LP | 902,086 6.200% |
902,086 (New Position) |
Filing History |
| 2023-08-03 4:30 pm Sale |
2023-08-01 | 13D | Alimera Sciences, Inc. ALIM |
Caligan Partners LP | 17,635,154 33.100% |
-915,040,279,903 (-100.00%) |
Filing History |
| 2023-07-03 5:17 pm Sale |
2023-07-03 | 13D | Standard BioTools Inc. LAB |
Caligan Partners LP | 7,797,454 9.900% |
-779,345 (-9.09%) |
Filing History |
| 2023-06-02 5:05 pm Purchase |
2023-05-31 | 13D | Exelixis, Inc. EXEL |
Caligan Partners LP | 910,730 0.280% |
60,730 (+7.14%) |
Filing History |
| 2023-05-18 5:24 pm Purchase |
2023-05-17 | 13D | Alimera Sciences, Inc. ALIM |
Caligan Partners LP | 915,057,915,057 9.990% |
915,057,190,341 (+126264245.63%) |
Filing History |
| 2023-03-28 5:00 pm Purchase |
2023-03-24 | 13D | Alimera Sciences, Inc. ALIM |
Caligan Partners LP | 724,716 9.990% |
313,189 (+76.10%) |
Filing History |
| 2023-03-27 5:20 pm Unchanged |
2023-03-23 | 13D | Exelixis, Inc. EXEL |
Caligan Partners LP | 850,000 0.260% |
0 (Unchanged) |
Filing History |
| 2023-03-20 5:00 pm Purchase |
2023-03-09 | 13D | Exelixis, Inc. EXEL |
Caligan Partners LP | 850,000 0.260% |
850,000 (New Position) |
Filing History |
| 2022-12-30 5:10 pm Sale |
2022-12-29 | 13D | Standard BioTools Inc. LAB |
Caligan Partners LP | 8,576,799 10.800% |
-2,868,037 (-25.06%) |
Filing History |
| 2022-12-09 5:00 pm Sale |
2022-12-09 | 13D | ADMA Biologics, Inc. ADMA |
Caligan Partners LP | 10,264,311 4.600% |
-628,926 (-5.77%) |
Filing History |